Journal
ACTA DERMATO-VENEREOLOGICA
Volume 93, Issue 5, Pages 557-561Publisher
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-1532
Keywords
seborrhoeic dermatitis; tacrolimus; maintenance therapy
Categories
Funding
- Astellas Pharma Inc.
- National Research Foundation of Korea (NRF)
- Ministry of Education, Science and Technology [2010-0023331]
- Astellas Pharma Korea
- National Research Foundation of Korea [2010-0023331] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The effectiveness of intermittent topical tacrolimus to prevent relapse in patients with stabilized facial seborrhoeic dermatitis has not been evaluated. The aim of this study was to determine whether proactive use of 0.1% tacrolimus ointment can keep adult facial seborrhoeic dermatitis in remission. A total of 75 patients who had stabilized facial seborrhoeic dermatitis after 2 weeks' (open-label induction) treatment with 0.1% tacrolimus were randomized in a double-blind fashion to treatment with 0.1% tacrolimus once a week, twice a week, or vehicle twice a week, for 10 weeks (maintenance). Significant improvement in erythema, scaling and pruritus compared with baseline was maintained during the maintenance phase in both tacrolimus groups, but not in the vehicle group. The mean recurrence rate according to global assessment was significantly higher in the tacrolimus once-weekly group than in the twice-weekly group. In conclusion, twice-weekly treatment with 0.1% tacrolimus ointment had superior effects in keeping facial seborrhoeic dermatitis in remission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available